Human cathelicidin, LL-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells

BMC Research Notes

Table 1 Trans-epithelial electrical resistance of ALI Calu-3 at 7 days post-infection

Treatment	Untreated^a	Prophylactic	Therapeutic
Mock-infected	392 ± 16 (range 376–451)	–	‒
RSV-A2	445 ± 152 (range 421–1098)	‒	‒
RSV-A2 + LL-37	‒	520 ± 105 (range 315–886)	313 ± 84 (range 184–594)
RSV-A2 + sLL-37	‒	560 ± 126 (range 289–936)	316 ± 114 (range 221–864)

The trans-epithelial electrical resistance (TEER) of five wells per treatment condition was evaluated at day 7 post-infection, and is presented as median Ω × cm² ± SEM of five individual wells per treatment condition, with the range of TEER measurements indicated in parentheses. No significant differences between prophylactic and therapeutic treatments or between mock-infected and infected treatment conditions were found using unpaired two-tailed statistical analysis. The data presented in this table is representative of three independent experiments
^a All experimental conditions were performed as one experiment; mock infected and RSV-A2 infected controls in the absence of peptide were performed simultaneously alongside prophylactic and therapeutic peptide treatments of infected ALI Calu-3

ISSN: 1756-0500